1. Technical Field
The present disclosure relates to attachment systems for staple line buttress materials. More particularly, the present disclosure relates to systems and methods of temporarily attaching staple line buttress materials to an anvil and staple containing cartridge of a surgical stapling instrument.
2. Background of Related Art
Surgical stapling instruments, or “stapling devices”, are employed by surgeons to sequentially or simultaneously apply one or more rows of fasteners, e.g., staples or two-part fasteners, to body tissue for the purpose of joining segments of body tissue together. Such devices generally include of a pair of jaws or finger-like structures between which the body tissue to be joined is placed. When the stapling device is actuated, or “fired”, longitudinally moving firing bars contact staple drive members in one of the jaws. The staple drive members push the surgical staples through the body tissue and into an anvil in the opposite jaw which crimps the staples closed. If tissue is to be removed or separated, a knife blade can be provided in the jaws of the device to cut the tissue between the lines of staples.
When stapling relatively thin or fragile tissues, it is important to effectively seal the staple line against air or fluid leakage. Additionally, it is often necessary to reinforce the staple line against the tissue to prevent tears in the tissue or pulling of the staples through the tissue. One method of preventing tears or pull through involves the placement of a biocompatible fabric reinforcing material, or “buttress” material, between the staple and the underlying tissue. In this method, a layer of buttress material is placed against the tissue and the tissue is stapled in conventional manner. In more recent methods, the buttress material is positioned on the stapling instrument itself prior to stapling the tissue. An exemplary example of this is disclosed in U.S. Pat. No. 5,542,594 to McKean et al. In McKean et al., a tube of buttress material is slipped over the jaw of the stapler. The stapler is then actuated to staple the subject tissue and secure the buttress material between the tissue and staple line to reinforce the tissue and staple line.
Some novel surgical staplers utilize fasteners or clips to temporarily connect buttress material to the jaws of the staplers. However, in some instances, it would be desirable to mold or machine structure into the jaws themselves to facilitate attachment of correspondingly structured buttress materials. It would be further desirable to provide such structure in a manner which does not interfere with the operation of a knife blade associated with the jaws.
There is disclosed a surgical stapler having a pair of jaws including a staple cartridge and an anvil. At least one of the jaws includes at least two longitudinally extending projections positioned at a first end of the first jaw. The surgical stapler also has a staple line buttress material releasably affixed to the at least one jaw and including recesses for receipt of the at least two projections. In one embodiment each of the at least two projections includes a neck portion and a bulbous portion. In an alternative embodiment, each of the at least two projections is relatively straight. The at least one jaw includes a longitudinally extending knife slot, the at least two projections being separated by the knife slot.
In a further embodiment, the at least one jaw includes two sets of the at least two projections and the at least one jaw includes a longitudinally extending knife slot. The knife slot separates the two sets of the at least two projections.
In particular embodiments, the at least one jaw includes a post at a second end and the buttress material includes a hole for receipt of the post. In a first version, the post is split to allow passage of a knife therebetween, whereas in a second version the post is solid.
In a specific embodiment, the post forms a mushroom shaped protrusion having a cap and the cap defines a flange for engagement with a portion of the buttress material.
In another embodiment the at least one jaw includes a pair of posts and the buttress material includes a pair of holes for receipt of the pair of posts. Each post of the pair of posts is positioned adjacent an outside edge of the buttress material. The at least one jaw also includes a longitudinally extending slot such that the pair of posts are separated by the slot.
In a particular embodiment, the at least one jaw includes a longitudinally extending slot and the post is positioned distally of a distal end of the slot and the buttress material has a hole for receipt of the post. The buttress material further includes a longitudinal slit extending through the area of the buttress material defining the hole.
Various embodiments of the presently disclosed interlocking buttress retention systems are disclosed herein with reference to the drawings, wherein:
Embodiments of the presently disclosed interlocking buttress material retention systems for use with surgical stapling instruments will now be described in detail with reference to the drawings wherein like numerals designate identical or corresponding elements in each of the several views. As is common in the art, the tell “proximal” refers to that part or component closer to the user or operator, i.e. surgeon or physician, while the term “distal” refers to that part or component further away from the user.
Referring now to
Staple clinching anvil 20 is provided with a layer of anvil buttress material 24 and staple cartridge 22 is provided with a layer of cartridge buttress material 26 in the manners described in more detail hereinbelow. An anvil buttress retention system 28 is incorporated into anvil 20 and anvil buttress material 24 and is provided to releasably secure anvil buttress material 24 to staple clinching anvil 20. Likewise, a cartridge buttress retention system 30 incorporated into staple cartridge 22 and cartridge buttress material 26 and is provided to releasably secure cartridge buttress material 26 to staple cartridge 22. Anvil buttress material 24 and cartridge buttress material 26 are provided to reinforce and seal staple lines applied to tissue by surgical stapler 10.
Anvil buttress retention system 28 and cartridge buttress retention system 30 are particularly configured to allow the respective buttress materials to be localized on inwardly facing surfaces of anvil 20 and staple cartridge 22 in order to facilitate passage of surgical stapler 10 into the body of a patient without risk of tearing or wrinkling of the respective buttress materials as surgical stapler 10 is inserted into and manipulated within the body of a patient.
Surgical stapler 10 further includes a trigger 32 movably mounted on handle 12. Actuation of trigger 32 initially operates to move anvil 20 from the open to the closed position relative to staple cartridge 22 and subsequently actuate surgical stapler 10 to apply lines of staples to tissue. In order to properly orient jaw assembly 16 relative to the tissue to be stapled, surgical stapler 10 is additionally provided with a rotation knob 34 mounted on handle 12. Rotation of rotation knob 34 relative to handle 12 rotates elongate tubular member 14 and jaw assembly 16 relative to handle 12 so as to properly orient jaw assembly 16 relative to the tissue to be stapled.
Referring to
Referring to
Referring still to
Some non-limiting examples of materials from which the buttress material may be made include but are not limited to poly(lactic acid), poly(glycolic acid), poly(hydroxybutyrate), poly (phosphazine), polyesters, polyethylene glycols, polyethylene oxides, polyacrylamides, polyhydroxyethylmethylacrylate, polyvinylpyrrolidone, polyvinyl alcohols, polyacrylic acid, polyacetate, polycaprolactone, polypropylene, aliphatic polyesters, glycerols, poly(amino acids), copoly(ether-esters), polyalkylene oxalates, polyamides, poly(iminocarbonates), polyalkylene oxalates, polyoxaesters, polyorthoesters, polyphosphazenes and copolymers, block copolymers, homopolymers, blends and combinations thereof.
In embodiments, natural biological polymers are used in forming the buttress material. Suitable natural biological polymers include, but are not limited to, collagen, gelatin, fibrin, fibrinogen, elastin, keratin, albumin, hydroxyethyl cellulose, cellulose, hydroxypropyl cellulose, carboxyethyl cellulose, chitan, chitosan, and combinations thereof. In addition, the natural biological polymers may be combined with any of the other polymeric materials described herein to produce the buttress material.
The buttress material may be porous or non-porous, or combinations of porous and non-porous layers. Where the buttress material is non-porous, buttress material may retard or prevent tissue ingrowth from surrounding tissues thereby acting as an adhesion barrier and preventing the formation of unwanted scar tissue. Thus, in embodiments, the buttress material possesses anti-adhesion properties. Techniques for forming non-porous layers from such materials are within the purview of those skilled in the art and include, for example, casting, molding and the like.
In embodiments, the buttress material is porous and possesses hemostatic properties. Where the buttress material is porous, it has openings or pores over at least a portion of a surface thereof. Suitable materials for forming the porous layer include, but are not limited to foams (e.g., open or closed cell foams). In embodiments, the pores may be in sufficient number and size so as to interconnect across the entire thickness of the porous layer. In other embodiments, the pores do not interconnect across the entire thickness of the porous layer. In yet other embodiments, the pores do not extend across the entire thickness of the porous layer, but rather are present at a portion of the surface thereof. In embodiments, the openings or pores are located on a portion of the surface of the porous layer, with other portions of the porous layer having a non-porous texture. Those skilled in the art reading the present disclosure will envision other pore distribution patterns and configurations for the porous layer.
Where the buttress material is porous, the pores may be formed using any method suitable to forming a foam or sponge including, but not limited to the lyophilization or freeze-drying of a composition. Suitable techniques for making foams are within the purview of those skilled in the art. Porous buttress materials can be at least 0.2 cm thick, in embodiments from about 0.3 to about 1.5 cm thick. Porous buttress materials can have a density of not more than about 75 mg/cm2 and, in embodiments below about 20 mg/cm2. The size of the pores in the porous buttress materials can be from about 20 μm to about 300 μm, in embodiments from about 100 μm to about 200 μm.
The buttress material may also include a reinforcement member. The reinforcement member may be associated with a porous or non-porous layer or may be positioned between a non-porous layer and a porous layer of the buttress material. Alternatively, the reinforcement member may be positioned entirely within one or more of the individual layers (i.e., embedded within the porous layer, the non-porous layer, or both) of the buttress material. It is also envisioned that the reinforcement member may be positioned at the surface of one of the layers making up the buttress material and, in embodiments, may be positioned at an exterior surface of the buttress material.
Some suitable non-limiting examples of reinforcement members include fabrics, meshes, monofilaments, multifilament braids, chopped fibers (sometimes referred to in the art as staple fibers) and combinations thereof. Where the reinforcement member is a mesh, it may be prepared using any technique known to those skilled in the art, such as knitting, weaving, tatting, knipling or the like. Where monofilaments or multifilament braids are used as the reinforcement member, the monofilaments or multifilament braids may be oriented in any desired manner. For example, the monofilaments or multifilament braids may be randomly positioned with respect to each other within the buttress material. As another example, the monofilaments or multifilament braids may be oriented in a common direction within the buttress material. Where chopped fibers are used as the reinforcement member, the chopped fibers may be oriented in any desired manner. For example, the chopped fibers may be randomly oriented or may be oriented in a common direction. The chopped fibers can thus form a non-woven material, such as a mat or a felt. The chopped fibers may be joined together (e.g., by heat fusing) or they may be unattached to each other. The chopped fibers may be of any suitable length. For example, the chopped may be from 0.1 mm to 100 mm in length, in embodiments, 0.4 mm to 50 mm in length. In an illustrative embodiment, the buttress material has randomly oriented chopped fibers that have not been previously fused together embedded within in the buttress material.
It is envisioned that the reinforcement member may be formed from any bioabsorbable, non-bioabsorbable, natural, or synthetic material previously described herein and combinations thereof. Where monofilaments or multifilament braids are used as the reinforcement member, any commercially available suture material may advantageously be employed as the reinforcement member.
In embodiments, at least one bioactive agent may be combined with the buttress material and/or any of the individual components (the porous layer, the non-porous layer and/or the reinforcement member) used to construct the buttress material. In these embodiments, the buttress material can also serve as a vehicle for delivery of the bioactive agent. The team “bioactive agent”, as used herein, is used in its broadest sense and includes any substance or mixture of substances that have clinical use. Consequently, bioactive agents may or may not have pharmacological activity per se, e.g., a dye, or fragrance. Alternatively a bioactive agent could be any agent which provides a therapeutic or prophylactic effect, a compound that affects or participates in tissue growth, cell growth, cell differentiation, an anti-adhesive compound, a compound that may be able to invoke a biological action such as an immune response, or could play any other role in one or more biological processes.
Examples of classes of bioactive agents which may be utilized in accordance with the present disclosure include anti-adhesives, antimicrobials, analgesics, antipyretics, anesthetics, antiepileptics, antihistamines, anti-inflammatories, cardiovascular drugs, diagnostic agents, sympathomimetics, cholinomimetics, antimuscarinics, antispasmodics, hormones, growth factors, muscle relaxants, adrenergic neuron blockers, antineoplastics, immunogenic agents, immunosuppressants, gastrointestinal drugs, diuretics, steroids, lipids, lipopolysaccharides, polysaccharides, and enzymes. It is also intended that combinations of bioactive agents may be used.
Anti-adhesive or anti-adhesion agents can be used to prevent adhesions from forming between the buttress material and the surrounding tissues opposite the target tissue. Some examples of these agents include, but are not limited to poly(vinyl pyrrolidone), carboxymethyl cellulose, hyaluronic acid, polyethylene oxide, poly vinyl alcohols and combinations thereof.
Suitable antimicrobial agents which may be included as a bioactive agent in the buttress material of the present disclosure include triclosan, also known as 2,4,4′-trichloro-2′-hydroxydiphenyl ether, chlorhexidine and its salts, including chlorhexidine acetate, chlorhexidine gluconate, chlorhexidine hydrochloride, and chlorhexidine sulfate, silver and its salts, including silver acetate, silver benzoate, silver carbonate, silver citrate, silver iodate, silver iodide, silver lactate, silver laurate, silver nitrate, silver oxide, silver palmitate, silver protein, and silver sulfadiazine, polymyxin, tetracycline, aminoglycosides, such as tobramycin and gentamicin, rifampicin, bacitracin, neomycin, chloramphenicol, miconazole, quinolones such as oxolinic acid, norfloxacin, nalidixic acid, pefloxacin, enoxacin and ciprofloxacin, penicillins such as oxacillin and pipracil, nonoxynol 9, fusidic acid, cephalosporins, and combinations thereof. In addition, antimicrobial proteins and peptides such as bovine lactoferrin and lactoferricin B may be included as a bioactive agent in the bioactive coating of the present disclosure.
Other bioactive agents which may be included as a bioactive agent in the buttress material in accordance with the present disclosure include: local anesthetics; non-steroidal antifertility agents; parasympathomimetic agents; psychotherapeutic agents; tranquilizers; decongestants; sedative hypnotics; steroids; sulfonamides; sympathomimetic agents; vaccines; vitamins; antimalarials; anti-migraine agents; anti-parkinson agents such as L-dopa; anti-spasmodics; anticholinergic agents (e.g. oxybutynin); antitussives; bronchodilators; cardiovascular agents such as coronary vasodilators and nitroglycerin; alkaloids; analgesics; narcotics such as codeine, dihydrocodeinone, meperidine, morphine and the like; non-narcotics such as salicylates, aspirin, acetaminophen, d-propoxyphene and the like; opioid receptor antagonists, such as naltrexone and naloxone; anti-cancer agents; anti-convulsants; anti-emetics; antihistamines; anti-inflammatory agents such as hormonal agents, hydrocortisone, prednisolone, prednisone, non-hormonal agents, allopurinol, indomethacin, phenylbutazone and the like; prostaglandins and cytotoxic drugs; estrogens; antibacterials; antibiotics; anti-fungals; anti-virals; anticoagulants; anticonvulsants; antidepressants; antihistamines; and immunological agents.
Other examples of suitable bioactive agents which may be included in the coating composition include viruses and cells, peptides, polypeptides and proteins, analogs, muteins, and active fragments thereof, such as immunoglobulins, antibodies, cytokines (e.g. lymphokines, monokines, chemokines), blood clotting factors, hemopoietic factors, interleukins (IL-2, IL-3, IL-4, IL-6), interferons (β-IFN, (α-IFN and γ-IFN), erythropoietin, nucleases, tumor necrosis factor, colony stimulating factors (e.g., GCSF, GM-CSF, MCSF), insulin, anti-tumor agents and tumor suppressors, blood proteins, gonadotropins (e.g., FSH, LH, CG, etc.), hormones and hormone analogs (e.g., growth hormone), vaccines (e.g., tumoral, bacterial and viral antigens); somatostatin; antigens; blood coagulation factors; growth factors (e.g., nerve growth factor, insulin-like growth factor); protein inhibitors, protein antagonists, and protein agonists; nucleic acids, such as antisense molecules, DNA and RNA; oligonucleotides; polynucleotides; and ribozymes.
Anvil buttress retention system 28 is provided to releasably secure anvil buttress material 24 to anvil 20 prior to stapling to tissue. Anvil buttress retention system 28 includes a distally raised region 46 formed on an undersurface 48 of anvil 20. As best shown in
Anvil buttress system 28 further includes a post 76 formed at a proximal end 78 of anvil 20. Anvil buttress material 24 is provided with a hole 80 at a proximal end 82 which is configured to engage post 76 and maintain anvil buttress material 24 taut across undersurface 48 of anvil 20.
As best shown in
Referring back for the moment to
Referring to
Referring to
Referring now to
Referring for the moment to
Referring back to
In order to assemble cartridge buttress retention system 30, hole 120 in cartridge buttress material 26 is positioned over protrusion 116 on distal end 118 of staple containing insert 110. Thereafter, proximal end 138 of cartridge buttress material 26 is positioned over proximal end 128 of staple containing insert 110. Slots 134 and 136 in anvil buttress material 26 are forced over projections 124 and 126 on staple containing insert 110 to engage anvil buttress material 26 with staple containing inset 110 in friction fit fashion.
Referring for the moment to
Referring now to
Referring to
With respect to
Referring now to
Referring now to
While not specifically shown, upon full actuation of surgical stapler 10, a knife blade associated with surgical stapler 10 and carried by driver 36 cuts tissue T, as well as anvil buttress material 24 and cartridge buttress material 26 between the rows of now clinched staples 102. Upon movement of anvil 20 to the open position spaced apart from staple cartridge 22, anvil buttress material 24 pulls away from anvil 20 and cartridge buttress material 26 pulls away from staple cartridge 22. Specifically, distal end 122 of cartridge buttress material 26 is cut through by the knife and is released from post 116. Proximal end 138 of cartridge buttress material 26 pulls free from longitudinal projections 124, 126 at proximal end 128 of staple containing insert 110. Likewise, distal end 66 of anvil buttress material 24 pulls free from proximally extending projections 50, 52 and proximal end 82 of anvil buttress material 24 pulls free from post 78.
The resulting tissue T, divided and stapled closed with staples 178, is best illustrated in
It will be understood that various modifications may be made to the embodiments disclosed herein. For example, various numbers of interlocking fingers or projections may be provided to increase the frictional contact between a jaw and an associated buttress material. Further, the disclosed buttress materials may be provided with various perforated regions to facilitate release from the disclosed fingers or projections and posts. Therefore, the above description should not be construed as limiting, but merely as exemplifications of particular embodiments. Those skilled in the art will envision other modifications within the scope and spirit of the claims appended hereto.
This application is a continuation of U.S. application Ser. No. 13/051,475 filed Mar. 18, 2011 now U.S. Pat. No. 8,083,119, which is a continuation of U.S. application Ser. No. 12/687,400 filed Jan. 14, 2010, now U.S. Pat. No. 7,909,224, which is a continuation application of Ser. No. 11/820,239 filed Jun. 18, 2007, now U.S. Pat. No. 7,665,646, and the disclosures of each of the above-identified applications are hereby incorporated by reference in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
3054406 | Usher | Sep 1962 | A |
3124136 | Usher | Mar 1964 | A |
4347847 | Usher | Sep 1982 | A |
4354628 | Green | Oct 1982 | A |
4452245 | Usher | Jun 1984 | A |
4605730 | Shalaby et al. | Aug 1986 | A |
4655221 | Devereux | Apr 1987 | A |
4834090 | Moore | May 1989 | A |
4838884 | Dumican et al. | Jun 1989 | A |
4930674 | Barak | Jun 1990 | A |
5002551 | Linsky et al. | Mar 1991 | A |
5014899 | Presty et al. | May 1991 | A |
5040715 | Green et al. | Aug 1991 | A |
5065929 | Schulze et al. | Nov 1991 | A |
5205459 | Brinkerhoff et al. | Apr 1993 | A |
5263629 | Trumbull et al. | Nov 1993 | A |
5314471 | Brauker et al. | May 1994 | A |
5344454 | Clarke et al. | Sep 1994 | A |
5392979 | Green et al. | Feb 1995 | A |
5397324 | Carroll et al. | Mar 1995 | A |
5425745 | Green et al. | Jun 1995 | A |
5441193 | Gravener | Aug 1995 | A |
5441507 | Wilk | Aug 1995 | A |
5468253 | Bezwada et al. | Nov 1995 | A |
5503638 | Cooper et al. | Apr 1996 | A |
5542594 | McKean et al. | Aug 1996 | A |
5549628 | Cooper et al. | Aug 1996 | A |
5575803 | Cooper et al. | Nov 1996 | A |
5653756 | Clarke et al. | Aug 1997 | A |
5683809 | Freeman et al. | Nov 1997 | A |
5690675 | Sawyer et al. | Nov 1997 | A |
5702409 | Rayburn et al. | Dec 1997 | A |
5752965 | Francis et al. | May 1998 | A |
5762256 | Mastri et al. | Jun 1998 | A |
5766188 | Igaki | Jun 1998 | A |
5769892 | Kingwell | Jun 1998 | A |
5782396 | Mastri et al. | Jul 1998 | A |
5799857 | Robertson et al. | Sep 1998 | A |
5810855 | Rayburn et al. | Sep 1998 | A |
5814057 | Oi et al. | Sep 1998 | A |
5833695 | Yoon | Nov 1998 | A |
5843096 | Igaki et al. | Dec 1998 | A |
5895412 | Tucker | Apr 1999 | A |
5895415 | Chow et al. | Apr 1999 | A |
5902312 | Frater et al. | May 1999 | A |
5908427 | McKean et al. | Jun 1999 | A |
5915616 | Viola et al. | Jun 1999 | A |
5931847 | Bittner et al. | Aug 1999 | A |
5964774 | McKean et al. | Oct 1999 | A |
5997895 | Narotam et al. | Dec 1999 | A |
6019791 | Wood | Feb 2000 | A |
6030392 | Dakov et al. | Feb 2000 | A |
6032849 | Mastri et al. | Mar 2000 | A |
6045560 | McKean et al. | Apr 2000 | A |
6063097 | Oi et al. | May 2000 | A |
6080169 | Turtel | Jun 2000 | A |
6099551 | Gabbay | Aug 2000 | A |
6149667 | Hovland et al. | Nov 2000 | A |
6155265 | Hammerslag | Dec 2000 | A |
6210439 | Firmin et al. | Apr 2001 | B1 |
6214020 | Mulhauser et al. | Apr 2001 | B1 |
6241139 | Milliman et al. | Jun 2001 | B1 |
6258107 | Balazs et al. | Jul 2001 | B1 |
6267772 | Mulhauser et al. | Jul 2001 | B1 |
6273897 | Dalessandro et al. | Aug 2001 | B1 |
6280453 | Kugel et al. | Aug 2001 | B1 |
6299631 | Shalaby | Oct 2001 | B1 |
6312457 | DiMatteo et al. | Nov 2001 | B1 |
6312474 | Francis et al. | Nov 2001 | B1 |
6325810 | Hamilton et al. | Dec 2001 | B1 |
6436030 | Rehil | Aug 2002 | B2 |
6454780 | Wallace | Sep 2002 | B1 |
6461368 | Fogarty et al. | Oct 2002 | B2 |
6503257 | Grant et al. | Jan 2003 | B2 |
6514283 | DiMatteo et al. | Feb 2003 | B2 |
6517566 | Hovland et al. | Feb 2003 | B1 |
6551356 | Rousseau | Apr 2003 | B2 |
6592597 | Grant et al. | Jul 2003 | B2 |
6638285 | Gabbay | Oct 2003 | B2 |
6652594 | Francis et al. | Nov 2003 | B2 |
6656193 | Grant et al. | Dec 2003 | B2 |
6669735 | Pelissier | Dec 2003 | B1 |
6677258 | Carroll et al. | Jan 2004 | B2 |
6685714 | Rousseau | Feb 2004 | B2 |
6704210 | Myers | Mar 2004 | B1 |
6723114 | Shalaby | Apr 2004 | B2 |
6726706 | Dominguez | Apr 2004 | B2 |
6736823 | Darois et al. | May 2004 | B2 |
6736854 | Vadurro et al. | May 2004 | B2 |
6746458 | Cloud | Jun 2004 | B1 |
6773458 | Brauker et al. | Aug 2004 | B1 |
6927315 | Heinecke et al. | Aug 2005 | B1 |
7128748 | Mooradian et al. | Oct 2006 | B2 |
7147138 | Shelton, IV | Dec 2006 | B2 |
7434717 | Shelton, IV et al. | Oct 2008 | B2 |
7438209 | Hess et al. | Oct 2008 | B1 |
7547312 | Bauman et al. | Jun 2009 | B2 |
7559937 | de la Torre et al. | Jul 2009 | B2 |
7604151 | Hess et al. | Oct 2009 | B2 |
7665646 | Prommersberger | Feb 2010 | B2 |
7744627 | Orban, III et al. | Jun 2010 | B2 |
7793813 | Bettuchi | Sep 2010 | B2 |
7823592 | Bettuchi et al. | Nov 2010 | B2 |
7845533 | Marczyk et al. | Dec 2010 | B2 |
7845536 | Viola et al. | Dec 2010 | B2 |
7909224 | Prommersberger | Mar 2011 | B2 |
8083119 | Prommersberger | Dec 2011 | B2 |
20020016626 | DiMatteo et al. | Feb 2002 | A1 |
20020019187 | Carroll et al. | Feb 2002 | A1 |
20020052622 | Rousseau | May 2002 | A1 |
20020091397 | Chen | Jul 2002 | A1 |
20020133236 | Rousseau | Sep 2002 | A1 |
20020138152 | Francis et al. | Sep 2002 | A1 |
20020151911 | Gabbay | Oct 2002 | A1 |
20020165559 | Grant et al. | Nov 2002 | A1 |
20020165562 | Grant et al. | Nov 2002 | A1 |
20020165563 | Grant et al. | Nov 2002 | A1 |
20020177859 | Monassevitch et al. | Nov 2002 | A1 |
20030065345 | Weadock | Apr 2003 | A1 |
20030065346 | Evens et al. | Apr 2003 | A1 |
20030083676 | Wallace | May 2003 | A1 |
20030088256 | Conston et al. | May 2003 | A1 |
20030105510 | DiMatteo et al. | Jun 2003 | A1 |
20030114866 | Ulmsten et al. | Jun 2003 | A1 |
20030120284 | Palacios et al. | Jun 2003 | A1 |
20030167064 | Whayne | Sep 2003 | A1 |
20030181927 | Wallace | Sep 2003 | A1 |
20030183671 | Mooradian et al. | Oct 2003 | A1 |
20030208231 | Williamson, IV et al. | Nov 2003 | A1 |
20040034377 | Sharkawy et al. | Feb 2004 | A1 |
20040092960 | Abrams et al. | May 2004 | A1 |
20040093029 | Zubik et al. | May 2004 | A1 |
20040107006 | Francis et al. | Jun 2004 | A1 |
20040116945 | Sharkawy et al. | Jun 2004 | A1 |
20040142621 | Carroll et al. | Jul 2004 | A1 |
20040172048 | Browning | Sep 2004 | A1 |
20040209059 | Foss | Oct 2004 | A1 |
20040215214 | Crews et al. | Oct 2004 | A1 |
20040215219 | Eldridge et al. | Oct 2004 | A1 |
20040215221 | Suyker et al. | Oct 2004 | A1 |
20040254590 | Hoffman et al. | Dec 2004 | A1 |
20040260315 | Dell et al. | Dec 2004 | A1 |
20050002981 | Lahtinen et al. | Jan 2005 | A1 |
20050021026 | Baily | Jan 2005 | A1 |
20050021053 | Heinrich | Jan 2005 | A1 |
20050021085 | Abrams et al. | Jan 2005 | A1 |
20050059996 | Bauman et al. | Mar 2005 | A1 |
20050059997 | Bauman et al. | Mar 2005 | A1 |
20050070929 | Dalessandro et al. | Mar 2005 | A1 |
20050118435 | DeLucia et al. | Jun 2005 | A1 |
20050228446 | Mooradian et al. | Oct 2005 | A1 |
20050245965 | Orban et al. | Nov 2005 | A1 |
20060004407 | Hiles et al. | Jan 2006 | A1 |
20060085034 | Bettuchi | Apr 2006 | A1 |
20060135992 | Bettuchi et al. | Jun 2006 | A1 |
20060173470 | Oray et al. | Aug 2006 | A1 |
20060178683 | Shimoji et al. | Aug 2006 | A1 |
20060212050 | D'Agostino et al. | Sep 2006 | A1 |
20060271104 | Viola et al. | Nov 2006 | A1 |
20070034669 | de la Torre et al. | Feb 2007 | A1 |
20070049953 | Shimoji et al. | Mar 2007 | A2 |
20070179528 | Soltz et al. | Aug 2007 | A1 |
20070203509 | Bettuchi | Aug 2007 | A1 |
20070203510 | Bettuchi | Aug 2007 | A1 |
20070246505 | Pace-Floridia et al. | Oct 2007 | A1 |
20080029570 | Shelton et al. | Feb 2008 | A1 |
20080082126 | Murray et al. | Apr 2008 | A1 |
20080110959 | Orban et al. | May 2008 | A1 |
20080125812 | Zubik et al. | May 2008 | A1 |
20080140115 | Stopek | Jun 2008 | A1 |
20080161831 | Bauman et al. | Jul 2008 | A1 |
20080161832 | Bauman et al. | Jul 2008 | A1 |
20080169327 | Shelton et al. | Jul 2008 | A1 |
20080169328 | Shelton | Jul 2008 | A1 |
20080169329 | Shelton et al. | Jul 2008 | A1 |
20080169330 | Shelton et al. | Jul 2008 | A1 |
20080169331 | Shelton et al. | Jul 2008 | A1 |
20080169332 | Shelton et al. | Jul 2008 | A1 |
20080169333 | Shelton et al. | Jul 2008 | A1 |
20080290134 | Bettuchi et al. | Nov 2008 | A1 |
20080308608 | Prommersberger | Dec 2008 | A1 |
20080314960 | Marczyk et al. | Dec 2008 | A1 |
20090001121 | Hess et al. | Jan 2009 | A1 |
20090001122 | Prommersberger et al. | Jan 2009 | A1 |
20090001123 | Morgan et al. | Jan 2009 | A1 |
20090001124 | Hess et al. | Jan 2009 | A1 |
20090001125 | Hess et al. | Jan 2009 | A1 |
20090001126 | Hess et al. | Jan 2009 | A1 |
20090001128 | Weisenburgh, II et al. | Jan 2009 | A1 |
20090001130 | Hess et al. | Jan 2009 | A1 |
20090005808 | Hess et al. | Jan 2009 | A1 |
20090030452 | Bauman et al. | Jan 2009 | A1 |
20090043334 | Bauman et al. | Feb 2009 | A1 |
20090078739 | Viola | Mar 2009 | A1 |
20090095791 | Eskaros et al. | Apr 2009 | A1 |
20090095792 | Bettuchi | Apr 2009 | A1 |
20090120994 | Murray et al. | May 2009 | A1 |
20090134200 | Tarinelli et al. | May 2009 | A1 |
20090206125 | Huitema et al. | Aug 2009 | A1 |
20090206126 | Huitema et al. | Aug 2009 | A1 |
20090206139 | Hall et al. | Aug 2009 | A1 |
20090206141 | Huitema et al. | Aug 2009 | A1 |
20090206142 | Huitema et al. | Aug 2009 | A1 |
20090206143 | Huitema et al. | Aug 2009 | A1 |
20090218384 | Aranyi | Sep 2009 | A1 |
20090277947 | Viola | Nov 2009 | A1 |
20090287230 | D'Agostino et al. | Nov 2009 | A1 |
20100012704 | Tarinelli Racenet et al. | Jan 2010 | A1 |
20100065606 | Stopek | Mar 2010 | A1 |
20100065607 | Orban, III et al. | Mar 2010 | A1 |
20100072254 | Aranyi et al. | Mar 2010 | A1 |
20100147921 | Olson | Jun 2010 | A1 |
20100147922 | Olson | Jun 2010 | A1 |
20100147923 | D'Agostino et al. | Jun 2010 | A1 |
20100243707 | Olson et al. | Sep 2010 | A1 |
20100243708 | Aranyi et al. | Sep 2010 | A1 |
20100243711 | Olson et al. | Sep 2010 | A1 |
20100249805 | Olson et al. | Sep 2010 | A1 |
20100264195 | Bettuchi | Oct 2010 | A1 |
20100282815 | Bettuchi et al. | Nov 2010 | A1 |
20110024476 | Bettuchi et al. | Feb 2011 | A1 |
20110024481 | Bettuchi et al. | Feb 2011 | A1 |
20110036894 | Bettuchi | Feb 2011 | A1 |
20110042442 | Viola et al. | Feb 2011 | A1 |
20110046650 | Bettuchi | Feb 2011 | A1 |
20110057016 | Bettuchi | Mar 2011 | A1 |
Number | Date | Country |
---|---|---|
199 24 311 | Nov 2000 | DE |
0 594 148 | Apr 1994 | EP |
0 327 022 | Apr 1995 | EP |
0 667 119 | Aug 1995 | EP |
1 064 883 | Jan 2001 | EP |
1 256 317 | Nov 2002 | EP |
1 520 525 | Apr 2005 | EP |
1 621 141 | Feb 2006 | EP |
1 759 640 | Mar 2007 | EP |
1 994 890 | Nov 2008 | EP |
2 005 894 | Dec 2008 | EP |
2 005 895 | Dec 2008 | EP |
WO 9005489 | May 1990 | WO |
WO 9701989 | Jan 1997 | WO |
WO 9713463 | Apr 1997 | WO |
WO 9817180 | Apr 1998 | WO |
WO 9945849 | Sep 1999 | WO |
WO 03082126 | Oct 2003 | WO |
WO 03105698 | Dec 2003 | WO |
WO 03105698 | Dec 2003 | WO |
WO 03105968 | Dec 2003 | WO |
WO 2006023578 | Mar 2006 | WO |
WO 2006044490 | Apr 2006 | WO |
WO 2006083748 | Aug 2006 | WO |
WO 2008057281 | May 2008 | WO |
WO 2008109125 | Sep 2008 | WO |
Number | Date | Country | |
---|---|---|---|
20120067936 A1 | Mar 2012 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 13051475 | Mar 2011 | US |
Child | 13307581 | US | |
Parent | 12687400 | Jan 2010 | US |
Child | 13051475 | US | |
Parent | 11820239 | Jun 2007 | US |
Child | 12687400 | US |